Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20890004 | 0.86 | IDO1 (0.35) | DRD3DRD2DRD4CA1CA2 | |
| SCHEMBL20909683 | 0.78 | DRD3 (0.46) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL9776786 | 0.77 | GRIN2B (0.50) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL20890009 | 0.75 | CA1 (0.49) | ACHECA1CA2MTNR1AMTNR1B | |
| SCHEMBL8056606 | 0.74 | DRD2 (0.68) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL8056603 | 0.74 | DRD2 (0.68) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL8056611 | 0.74 | DRD2 (0.68) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL20890076 | 0.74 | DRD2 (0.43) | DRD3DRD2DRD4ACHECA1 | |
| SCHEMBL823055 | 0.73 | MTNR1A (0.61) | DRD3DRD2DRD4CA1CA2 | |
| SCHEMBL4606877 | 0.73 | MTNR1A (0.61) | DRD3DRD2DRD4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | DRD3 4178/4885DRD2 4370/4885DRD4 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.